| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 49 companies in the Life Sciences Tools & Services industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 5, 2026 | NTRA Natera, Inc. | Rabinowitz Matthew59 | Executive Chairman | Sell | 7,708 | $213.05 | $1,642,210.82 | - | - | - | |
| May 4, 2026 | NTRA Natera, Inc. | Brophy Michael Burkes47 | Chief Financial Officer | Sell | 795 | $208.79 | $165,984.26 | -0.7% | - | - | |
| May 1, 2026 | NTRA Natera, Inc. | Moshkevich Solomon | President, Clinicaldiagnostics | Sell | 3,405 | $203.69 | $693,559.95 | -0.3% | - | - | |
| May 1, 2026 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 107 | $206.16 | $22,059.12 | - | - | - | |
| May 1, 2026 | NTRA Natera, Inc. | Fesko John | President, Chief Bus. Officer | Sell | 291 | $206.16 | $59,992.56 | -0.2% | - | - | |
| May 1, 2026 | NTRA Natera, Inc. | Rabinowitz Daniel48 | Sec. And Chief Legal Officer | Sell | 330 | $206.16 | $68,032.80 | -0.1% | - | - | |
| May 1, 2026 | NTRA Natera, Inc. | Chapman Steven Leonard56 | CEO And President | Sell | 902 | $206.16 | $185,956.32 | -0.6% | - | - | |
| Apr 29, 2026 | NTRA Natera, Inc. | Brophy Michael Burkes47 | Chief Financial Officer | Sell | 5,063 | $197.84 | $1,001,645.17 | -1.2% | - | - | |
| Apr 29, 2026 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 3,544 | $197.43 | $699,692.50 | -0.3% | - | - | |
| Apr 27, 2026 | NTRA Natera, Inc. | Rabinowitz Daniel48 | Sec. And Chief Legal Officer | Sell | 1,861 | $204.09 | $379,811.07 | -0.4% | - | - | |
| Apr 27, 2026 | WST West Pharmaceutical Services, Inc. | Favorite Annette F | Sr. VP &Chief Hr Officer | Sell | 2,817 | $305.20 | $859,753.47 | -14.3% | - | - | |
| Apr 27, 2026 | NTRA Natera, Inc. | Fesko John | President, Chief Bus. Officer | Sell | 1,688 | $204.10 | $344,516.88 | -0.4% | - | - | |
| Apr 27, 2026 | TWST Twist Bioscience Corporation | Starovasnik Melissa A. | Director | Sell | 500 | $61.83 | $30,915.00 | -1.9% | - | - | |
| Apr 27, 2026 | NTRA Natera, Inc. | Chapman Steven Leonard56 | CEO And President | Sell | 5,838 | $204.14 | $1,191,774.74 | -1.9% | - | - | |
| Apr 27, 2026 | WST West Pharmaceutical Services, Inc. | Winters Chad | VP, Chief Accounting Officer | Sell | 896 | $300.67 | $269,399.24 | -37.0% | - | - | |
| Apr 27, 2026 | NTRA Natera, Inc. | Moshkevich Solomon | President, Clinicaldiagnostics | Sell | 2,182 | $204.10 | $445,340.90 | -0.7% | - | - | |
| Apr 27, 2026 | IMDX Insight Molecular Diagnostics Inc. | Broadwood Partners, L.P.60 | 10% Owner | Buy | 570,184 | $3.56 | $2,032,251.45 | +0.8% | - | - | |
| Apr 23, 2026 | TWST Twist Bioscience Corporation | Finn Patrick John73 | President And COO | Sell | 2,321 | $60.76 | $141,026.28 | -0.8% | - | - | |
| Apr 20, 2026 | RVTY Revvity, Inc. | Gonzales Anita | Vice President And CAO | Sell | 80 | $92.80 | $7,424.00 | -1.1% | - | - | |
| Apr 20, 2026 | IMDX Insight Molecular Diagnostics Inc. | Broadwood Partners, L.P.60 | 10% Owner | Buy | 182,861 | $3.57 | $652,875.63 | +0.3% | - | - | |
| Apr 17, 2026 | NTRA Natera, Inc. | Sheena Jonathan46 | Director, Co-founder | Sell | 1,500 | $199.63 | $299,440.95 | -3.6% | - | - | |
| Apr 9, 2026 | TWST Twist Bioscience Corporation | Laponis Adam58 | Chief Financial Officer | Sell | 2,597 | $49.89 | $129,561.73 | -2.0% | - | - | |
| Apr 8, 2026 | GRAL Grail, Inc. | Ragusa Robert P | Chief Executive Officer | Sell | 123,502 | $49.92 | $6,164,923.44 | -19.2% | - | - | |
| Apr 8, 2026 | GRAL Grail, Inc. | Freidin Aaron | Chief Financial Officer | Sell | 45,806 | $49.92 | $2,286,525.59 | -14.9% | - | - | |
| Apr 8, 2026 | GRAL Grail, Inc. | Ofman Joshua J. | President | Sell | 61,665 | $49.92 | $3,078,168.80 | -14.2% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.